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Aims. Hyperinsulinemia in overweight status, obesity, and type 2 diabetes mellitus (DM) is often accompanied by cancer. Gender
is important in cancer epidemiology, clinical presentation, and response to therapy in diﬀerent histological types of malignancy.
Insuﬃcient information is available concerning gender diﬀerences in DM with organ-speciﬁc and nonorgan-speciﬁc cancers. This
study aimed to analyze gender diﬀerences in hospitalized cancer patients with or without type 2 DM. Methods.W er e t r o s p e c t i v e l y
reviewed ten years of patients hospitalized in one institution, enrolling 36,457 female and 50,004 male cancer patients of which
5,992 females and 8,345 males were diagnosed as type 2 DM. Results. Statistically signiﬁcant increases in incidence of type 2 DM
were found in patients of both genders with pancreatic, liver, and urinary tract cancer. Increased incidence of type 2 DM was
found in lung and hematologic malignancies in females and prostate cancer in males. Increases in mortality rates of females with
type 2 DM (2.98%) were higher than those in males. DM increased mortality rates in gender-speciﬁc cancers from 1.91% (uterus,
HR: 1.33) to 5.04% (ovary, HR: 1.49). Conclusion. Type 2 DM increased mortality of cancer patients of both genders, with higher
increases in gender-speciﬁc than in nongender-speciﬁc cancers.
1.Introduction
Mortality rates for cancer with or without type 2 diabetes
mellitus (DM) are much higher than in the general popu-
lation worldwide [1–3]. Understanding the primary cause
of this excess mortality is important in order to determine
interventions to decrease mortality rates in these cases. The
increased mortality has been attributed both to cancer treat-
ment, underlying disease, or acute and chronic complica-
tions of DM, such as, renal and cardiovascular diseases
(CVD). Previous reports have shown that DM may increase
mortality rates of diﬀerent cancers; in addition, we need to
knowthatCVDasapredominatecomplicationintype2DM
mayinﬂuencetheresultsoftreatmentindiﬀerentgenderand
a g eg r o u p sw i t ht y p e2D M[ 4–6]. Only a handful of recent
reports address cause-speciﬁc mortality in population-based
type 1 diabetes cohorts [7–12] and even fewer studies had
long-term followup (15 years) [10, 11]. The aim of this study
was to investigate gender diﬀerences in cancer patients with
or without type 2 DM. Mortality causes are analyzed in
diﬀerent cancer histotypes.
2. Patients andMethods
2.1. Study Population. Patients were identiﬁed through
admission data from Chang Gung Memorial Hospital
(CGMH) in Linkou, Taiwan, between January 2001 and
December 2010. Patients were 20 years of age and
were included if the indication for hospital admission
was a diagnosis of type 2 DM or malignancy. Type 2
DM was deﬁned as a fasting glucose level >126mg/dL
orapostprandialglucoselevel>200mg/dL[13];thediagnos-
ticcodeofmalignancywasdeﬁnedascodesfrom140–208.912 Experimental Diabetes Research
0       
5
10
15
20
25
30
35
40
Male:
Age group
(
%
)
DM (+) cancer (−)
DM (−) cancer (+)
DM (+) cancer (+)
2
0
–
2
9
3
0
–
3
9
4
0
–
4
9
5
0
–
5
9
6
0
–
6
9
7
0
–
7
9
8
0
–
8
9
9
0
–
(a)
Female:
0       
5
10
15
20
25
30
35
40
(
%
)
Age group
DM (+) cancer (−)
DM (−) cancer (+)
DM (+) cancer (+)
2
0
–
2
9
3
0
–
3
9
4
0
–
4
9
5
0
–
5
9
6
0
–
6
9
7
0
–
7
9
8
0
–
8
9
9
0
–
(b)
Figure 1: Percentage of cancer patients with and without type 2 DM and type 2 DM without cancer in diﬀerent age groups of both genders.
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Figure 2: Total mortality rates of both genders diagnosed as cancer
with and without type 2 DM.
in the ICD-9 clinical modiﬁcation format. A total of 149,491
cancer or type 2 DM patients included 81,564males and
67,927females. A total of 77,387 patients were diagnosed as
type 2 DM. Most patients with type 2 DM were admitted for
reasonsotherthanDM.Diseasecodesfortype2DMwithout
cancer included infectious disease, cardiovascular episode,
pulmonary diseases, accidence, and obstetric complications.
In contrast, most cancer patients with or without DM were
admitted for cancer diagnosis or therapy. Patients with type
1 DM were excluded from this study after ICD-9 code
sorting. Figure 1 illustrates age and gender distributions of
hospitalized type 2 DM or cancer patients in this study.
Death certiﬁcates from 2001 to 2010 were coded in
ICD-9 [14]. Patients with malignant neoplasms required
the diagnosis to be validated by at least two specialists
based on examination of medical records, laboratory and
imaging results, and histologic or cytologic analyses. Patients
diagnosed with malignant neoplasms were categorized into
diﬀerent groups according to the anatomic organ system. All
subjects were Chinese residents of Taiwan. The study was
approved by the Institutional Review Board of CGMH.
2.2. Statistical Analysis. All data analyses were performed
using SPSS (version 16.0; SPSS, Inc., Chicago, IL, USA)
[15]. The incidence proportions were computed for various
cancers and type 2 DM by gender and age. Logistic regres-
sion, adjusted for age and gender, was used to estimate the
hazard ratios (HRs) and 95% conﬁdence intervals (CIs) for
associationsbetweentheDMmortalityrateandthenon-DM
mortality rate of speciﬁc cancers. Chi-square tests were used
todetermineifthediﬀerenceinfrequencyofaspeciﬁccancer
between patients with and without DM was signiﬁcant.
3. Results
A total of 86,461 cases were diagnosed with malignancies
including 14,337 patients with type 2 DM, including 36,457Experimental Diabetes Research 3
Table 1: Number of cancer patients and DM (%) categorized in diﬀerent gender and histological pattern.
Histology Female Male Total F/M ratio
Total (DM) number [%] Total (DM) number [%] Total (DM) number [%]
Pancreas 646 (220) [34.1%]∗ 991 (295) [29.8%]∗ 1,637 (515) [31.5%] 0.65
Liver 3,782 (1,030) [27.2%]∗ 10,246 (2,207) [21.5%]∗ 14,028 (3,237) [23.1%] 0.37
Urinary tract 1,565 (363) [23.2%]∗ 2,633 (501) [19.0%]∗ 4,198 (864) [20.6%] 0.59
Lung 3,600 (689) [19.1%]∗ 7,158 (1,219) [17.0%] 10,758 (1,908) [17.7%] 0.50
Gastric 1,639 (286) [17.4%] 2,831 (424) [15.0%] 4,470 (710) [15.9%] 0.58
Hematologic 1,844 (346) [18.8%]∗ 2,335 (394) [16.9%] 4,179 (740) [17.7%] 0.79
Colon 5,049 (865) [17.1%] 6,339 (1,026) [16.2%] 11,388 (1,891) [16.6%] 0.80
Skin 297 (55) [18.5%] 390 (81) [20.8%] 687 (136) [19.8%] 0.76
Oropharynx 631 (89) [14.1%] 5,846 (752) [12.9%] 6,477 (841) [13.0%] 0.11
NPC 601 (71) [11.8%]∧ 1,551 (150) [9.7%]∧ 2,152 (221) [10.3%] 0.39
Esophagus 135 (18) [13.3%] 1,897 (201) [10.6%]∧ 2,032 (219) [10.8%] 0.07
Thyroid 1,460 (118) [8.1%]∧ 455 (51) [11.2%]∧ 1,915 (169) [8.8%] 3.21
Breast (F) 6,152 (572) [9.3%]
∧ — 6,152 (572) [9.3%] —
Cervical (F) 3,388 (416) [12.3%]∧ — 3,388 (416) [12.3%] —
Ovary (F) 1,379 (170) [12.3]∧ —
1,379 (170) [12.3] —
Uterus (F) 1,450 (246) [17.0%] — 1,450 (246) [17.0%] —
Prostate (M) — 2,905 (601) [20.7%]∗ 2,905 (601) [20.7%] —
Others 3,920 (658) [16.8%] 6,099 (792) [13.0%] 10,019 (1,450) [14.5%] 0.64
Total 36,457 (5,992) [16.4%] 50,004 (8,345) [16.7%] 86,461 (14,337) [16.6%] 0.73
Table 2: The hazard ratio concerning mortality with or without DM of admission cancer patients categorized in diﬀerent cancer types and
genders.
Cancers
Male Female
Non-DM DM Non-DM DM
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Total cancer 2.50 [2.34, 2.66] 3.31 [2.78, 3.31] 2.27 [2.11, 2.45] 3.28 [2.96, 3.63]
Pancreas 2.19 [1.77, 2.69] 2.00 [1.44, 2.77] 1.91 [1.40, 2.61] 2.66 [1.82, 3.89]
Liver 1.65 [1.53, 1.78] 1.75 [1.53, 2.00] 1.63 [1.42, 1.87] 2.05 [1.68, 2.45]
Uterus (F) 0.99 [0.78, 1.26] 1.34 [0.84, 2.15]
Urinary tract 0.86 [0.72, 1.02] 0.95 [0.68, 1.33] 0.84 [0.65, 1.09] 1.39 [0.95, 2.04]
Lung 1.99 [1.84, 2.16] 2.34 [1.99, 2.74] 2.41 [2.15, 2.71] 2.75 [2.21, 3.42]
Gastric 1.32 [1.15, 1.51] 1.73 [1.30, 2.31] 1.67 [1.39, 2.02] 1.91 [1.31, 2.79]
Prostate (M) 0.47 [0.38, 0.59] 0.82 [0.59, 1.13]
Hematologic 1.94 [1.70, 2.22] 2.16 [1.63, 2.85] 2.13 [1.81, 2.50] 2.22 [1.60, 3.08]
Colon 0.78 [0.70, 0.88] 1.00 [0.79, 1.25] 1.18 [1.05, 1.34] 1.21 [0.93, 1.57]
Skin 0.57 [0.33, 0.97] 0.94 [0.41, 2.17] 0.48 [0.22, 1.01] 0.30 [0.04, 2.14]
Cervical (F) 1.07 [0.91, 1.24] 1.67 [1.20, 2.33]
Oropharynx 0.96 [0.86, 1.07] 1.21 [0.94, 1.55] 0.84 [0.57, 1.24] 1.37 [0.63, 2.96]
Ovary (F) 1.87 [1.55, 2.26] 2.93 [1.93, 4.45]
NPC 1.18 [0.98, 1.42] 1.54 [0.93, 2.55] 1.53 [1.13, 2.08] 3.62 [1.98, 6.61]
Breast (F) 0.96 [0.85, 1.08] 1.50 [1.12, 2.01]
Esophagus 2.71 [2.39, 3.08] 3.79 [2.73, 5.26] 2.55 [1.50, 4.32] 2.01 [0.46, 8.74]
Thyroid 0.24 [0.12, 0.49] 1.01 [0.37, 2.82] 0.18 [0.11, 0.30] 1.14 [0.55, 2.33]4 Experimental Diabetes Research
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Figure 3: Mortality of individual nongender-speciﬁc cancer types in DM and non-DM groups.
females and 50,004 males. Among them, 5,992 (16.4%)
females and 8,345 (16.7%)males (P>0.05) were diagnosed
as type 2 DM. The ratios of DM in female cancer patients
were shown to be higher than in males after age 60 years.
Table 1 demonstrates the diﬀerent histological patterns of
cancer patients in both genders categorized in the DM and
non-DM groups. The diﬀerent histotypes with DM were
variable, from 8.8% (thyroid cancer) to 31.5% (pancreas
cancer). A statistically signiﬁcant diﬀerence was found in
the increased incidence of type 2 DM in patients with pan-
creas, liver, and urinary tract in both genders. In addition,
increased incidence of type 2 DM of lung and hematologic
malignancies in females and prostate cancer in males was
found. A decreased incidence of DM was demonstrated inExperimental Diabetes Research 5
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Figure 4: Mortality rates in gender-speciﬁc cancer with and without type 2 DM.
patients with thyroid and nasopharyngeal cancer in both
genders. Furthermore, decreases in type 2 diabetes mellitus
were noted in breast, cervical, and ovarian cancers in females
and esophageal cancer in males.
Table 2 shows HRs of mortality in cancer patients with
DM and non-DM groups of diﬀerent genders and histologi-
cal types compared with type 2 DM patients without cancer.
Signiﬁcant increased mortality was shown in all pancreas,
liver, lung, gastric, and hematologic cancers in both genders,
and esophageal cancer in males in both DM and non-DM
groups was higher than in DM without cancer. In contrast,
in non-DM patients with prostate, colon, skin, and thyroid
cancer in males and thyroid cancer in females without DM
showed lower mortality rates than in DM without cancer.
Figure 2 illustrates total mortality rates of both genders
diagnosed as cancer with and without type 2 DM in diﬀerent
age groups. DM with cancer in both genders demonstrated
higher total mortality in all age groups except in those over
age 90 years than in non-DM patients. Two peaks of mor-
tality rates were shown in DM with cancer in ages younger
than 40 years and in the 80–89-year-old age groups. Figure 2
illustrates case numbers and percentages of cancer with or
without type 2 DM in both genders. In addition, increased
mortality rates of DM patients with HR were described.
Mortality rates of females with DM and cancer increased
2.98%, which was higher than that in males (1.87%) (HR:
1.40 in female, 1.19 in male; P<0.01) (Figure 2).
Comparison of individual cancers of nongender-specif-
ic types in DM and non-DM groups is illustrated in
Figures 3(a) and 3(b). Type 2 DM increased mortality from
0.72% (pancreatic cancer, HR: 1.05) to 5.78% (thyroid can-
cer, HR 5.39) compared with non-DM patients. In addi-
tion, DM increased mortality rates in gender-speciﬁc cancer
from 1.91% (uterus, HR: 1.33) to 5.04% (ovary, HR: 1.49)
(Figure 4). In all patients, type 2 DM increased mortality
in gender-speciﬁc cancer more than in nongender-speciﬁc
cancer (2.69% versus 1.76%; HR: 1.46 versus 1.18; P<0.01).
4. Discussion
Theincidenceoftype2DMinhospitalizedcancerpatientsin
this study was slightly higher than in the general population
in Taiwan; however, it was lower than in patients in previous
studies with other comorbidities [16, 17]. In this cohort,
age and gender showed characteristic patterns of type 2 DM
with cancer. In the whole group, incidence of type 2 DM
in cancer patients was not diﬀerent between genders, but
increased incidence of type 2 DM in females over age 60 was
noted. These age and gender eﬀects were partly due to the
loss of estrogen protection in females during menopause as
demonstrated in our previous study in healthy subjects [18].
In this study, incidence of type 2 DM in diﬀerent cancer
types was signiﬁcantly lower than in cancer patients of both
genders with nasopharyngeal and thyroid cancer. Recent
studies showed that increased body mass index (BMI) may
increase thyroid cancer incidence and risk [19, 20]. Other-
wise, type 2 DM did not increase incidence of thyroid cancer
in our recent study [21]. However, total mortality of thyroid
cancer patients was increased in those with with type 2
DM. This result warrants further conﬁrmation because most
thyroid cancer patients have long-term followup. Until now,
we have no information concerning type 2 DM incidence
in patients with nasopharyngeal cancer. Contrary to our
results, one study demonstrated that DM may result in worse
disease-free survival of cancer patients than non-DM [22].
Oncogenesis is a multifactorial and multigenetic event.
Gender and DM are known as important factors in the
incidence and prognosis of many cancers. Compared with
previous studies, mortality from site-speciﬁc malignancies
is diﬀerent in type 2 diabetic patients than in the non-DM6 Experimental Diabetes Research
population and a slight increase in the overall mortality from
malignancies was observed in diabetic patients, achieving
statistical signiﬁcance in women but not in men [23]. In that
study, type 2 DM had higher increases in mortality rates of
female cancer patients than in male cancer patients.
In this study cohort of hospitalized patients, there were
more males with nongender-speciﬁc cancers; however,
females had a higher percentage of type 2 DM in nongender-
speciﬁc cancer. The increased number of type 2 DM patients
with cancer after age 60 years is partly due to loss of the
estrogen protection eﬀect of menopause; in addition, in-
sulin-like growth factor 1 (IGF-1) may play a role. In a
recent report, males had signiﬁcantly higher serum IGF-
1 levels than females in the age groups 18–24 and 50–69
but not in others [24]. Otherwise, other growth factors and
environmental factors may play a role in oncogenesis, which
n e e d st ob ef u r t h e ri n v e s t i g a t e d .
In conclusion, type 2 DM increased overall mortality of
cancer patients in both genders. A higher increment of mor-
tality is found in females with type 2 DM with cancer than
in males when compared with non-DM patients. Increased
mortalityratesofgender-speciﬁccancerinpatientswithtype
2DMwerehigherthaninnongender-speciﬁccancerpatients
compared with those of non-DM cancer patients.
References
[1] K. Gu, C. C. Cowie, and M. I. Harris, “Mortality in adults with
and without diabetes in a National cohort of the U.S. Popula-
tion, 1971–1993,” Diabetes Care, vol. 21, no. 7, pp. 1138–1145,
1998.
[2] R. Nishimura, R. E. LaPorte, J. S. Dorman, N. Tajima, D.
Becker, and T. J. Orchard, “Mortality trends in type 1 diabetes:
the allegheny county (pennsylvania) registry 1965–1999,”
Diabetes Care, vol. 24, no. 5, pp. 823–827, 2001.
[3] M. Matsushima, R. E. LaPorte, M. Maruyama, K. Shimizu, R.
Nishimura,andN.Tajima,“Geographicvariationinmortality
among individuals with youth-onset diabetes mellitus across
the world,” Diabetologia, vol. 40, no. 2, pp. 212–216, 1997.
[4] T. Deckert, J. E. Poulsen, and M. Larsen, “Prognosis of diabet-
ics with diabetes onset before the age of thirtyone. I. Survival,
causes of death, and complications,” Diabetologia, vol. 14, no.
6, pp. 363–370, 1978.
[5] A. R. Christlieb, J. H. Warram, A. S. Kr´ olewski et al., “Hy-
pertension: the major risk factor in juvenile-onset insulin-
dependent diabetics,” Diabetes, vol. 30, no. 2, pp. 90–96, 1981.
[6] J. S. Dorman, R. E. Laporte, and L. H. Kuller, “The Pittsburgh
insulin-dependent diabetes mellitus (IDDM) morbidity and
mortality study. Mortality results,” Diabetes,v o l .3 3 ,n o .3 ,p p .
271–276, 1984.
[ 7 ] N .A .R o p e r ,R .W .B i l o u s ,W .F .K e l l y ,N .C .U n w i n ,a n dV .M .
Connolly, “Cause-speciﬁc mortality in a population with dia-
betes: south tees diabetes mortality study,” Diabetes Care, vol.
25, no. 1, pp. 43–48, 2002.
[8] E. Weiderpass, G. Gridley, O. Nyr´ en, G. Pennello, A. S.
Landstr¨ om, and A. Ekbom, “Cause-speciﬁc mortality in a
cohort of patients with diabetes mellitus: a population-based
study in Sweden,” Journal of Clinical Epidemiology, vol. 54, no.
8, pp. 802–809, 2001.
[9] I. M¨ uhlhauser, P. T. Sawicki, M. Blank, H. Overmann, R. Ben-
der, and M. Berger, “Prognosis of persons with type 1 diabetes
on intensiﬁed insulin therapy in relation to nephropathy,”
JournalofInternalMedicine,vol.248,no.4,pp.333–341,2000.
[10] S. I. Dawson, J. Willis, C. M. Florkowski, and R. S. Scott,
“Cause-speciﬁc mortality in insulin-treated diabetic patients:
a 20-year follow-up,” Diabetes Research and Clinical Practice,
vol. 80, no. 1, pp. 16–23, 2008.
[ 1 1 ]T .S k r i v a r h a u g ,H .J .B a n g s t a d ,L .C .S t e n e ,L .S a n d v i k ,K .F .
Hanssen, and G. Joner, “Long-term mortality in a nationwide
cohortofchildhood-onsettype1diabeticpatientsinNorway,”
Diabetologia, vol. 49, no. 2, pp. 298–305, 2006.
[12] S. P. Laing, A. J. Swerdlow, S. D. Slater et al., “The British Dia-
betic Association Cohort Study, II: cause-speciﬁc mortality in
patientswithinsulin-treateddiabetesmellitus,”DiabeticMedi-
cine, vol. 16, no. 6, pp. 466–471, 1999.
[13] American Diabetes Association, “Diagnosis and classiﬁcation
of diabetes mellitus,” Diabetes Care, vol. 33, supplement 1, pp.
S62–S69, 2010.
[14] WorldHealthOrganization, InternationalClassiﬁcationofDis-
eases, World Health Organization, Geneva, Switzerland, 9th
edition, 1978.
[15] R. Levesque, SPSS Programming and Data Management for
SPSS 16.0: A Guide for SPSS and SAS Users, SPSS, Chicago,
Ill, USA, 2007.
[16] C. H. Lee, P. Y. Liu, L. M. Tsai et al., “Characteristics of hospi-
talized patients with atrial ﬁbrillation in taiwan: a nationwide
observation,” AmericanJournal of Medicine,vol. 120, no. 9,pp.
819.e1–819.e7, 2007.
[17] C. H. Tseng, “Clinical features of heart failure hospitalization
in younger and elderly patients in Taiwan,” European Journal
of Clinical Investigation, vol. 41, no. 6, pp. 597–604, 2011.
[18] R. de Marco, F. Locatelli, G. Zoppini, G. Verlato, E. Bonora,
and M. Muggeo, “Cause-speciﬁc mortality in type 2 diabetes:
the verona diabetes study,” Diabetes Care, vol. 22, no. 5, pp.
756–761, 1999.
[19] J. E. Paes, K. Hua, R. Nagy, R. T. Kloos, D. Jarjoura, and M.
D. Ringel, “The relationship between body mass index and
thyroid cancer pathology features and outcomes: a clinico-
pathological cohort study,” Journal of Clinical Endocrinology
and Metabolism, vol. 95, no. 9, pp. 4244–4250, 2010.
[20] T. Mijovi´ c, J. How, M. Pakdaman et al., “Body mass index in
the evaluation of thyroid cancer risk,” Thyroid, vol. 19, no. 5,
pp. 467–472, 2009.
[21] W.-K. Chiou, B.-Y. Huang, W.-Y. Chou, H.-F. Weng, and J.-
D. Lin, “Incidence of cancer in diabetic and non-diabetic
hospitalized adult patients,” Asian Paciﬁc Journal of Cancer
Prevention, vol. 12, pp. 1577–1581, 2011.
[22] H. Liu, Y. Xia, and N. Cui, “Impact of diabetes mellitus on
treatment outcomes in patients with nasopharyngeal cancer,”
Medical Oncology, vol. 23, no. 3, pp. 341–346, 2006.
[23] G. Verlato, G. Zoppini, E. Bonora, and M. Muggeo, “Mortality
fromsite-speciﬁcmalignanciesintype2diabeticpatientsfrom
Verona,” Diabetes Care, vol. 26, no. 4, pp. 1047–1051, 2003.
[24] F .Ba yram,V .T .Gedik,¨ O.Demiretal.,“Epidemiologicsurvey:
reference ranges of serum insulin-like growth factor 1 levels in
Caucasian adult population with immunoradiometric assay,”
Endocrine, vol. 40, no. 2, pp. 304–309, 2011.